Metachromatic Leukodystrophy

This is a rare genetic disease that affects the brain and nervous system. It causes the white matter in the brain to break down, leading to problems with walking, talking, and eventually, paralysis. It's caused by a missing enzyme that affects the myelin sheath, which protects nerve fibers.

Condition

What people with Metachromatic Leukodystrophy report

Every report comes from a Lived member, sent anonymously.

Have you had Stem Cell Transplant for Metachromatic Leukodystrophy?

NameHow it went

About Metachromatic Leukodystrophy

What It Is

Metachromatic leukodystrophy (MLD) is a rare inherited disease that gradually destroys myelin, the fatty coating that insulates nerve fibers and lets signals travel quickly. It happens because the body cannot break down fats called sulfatides, which build up and damage the cells that make myelin in the brain, spinal cord and the nerves running to the limbs. As that damage spreads, people lose movement, coordination, thinking and communication skills they once had. MLD is grouped by the age symptoms begin, and the age largely predicts how fast it progresses. The late infantile form, the most common, usually starts before about two and a half years of age: a toddler stops gaining skills, then begins losing walking and speech, and decline is rapid. Juvenile MLD begins between about two and a half and 16 years, often with clumsiness, falling behind at school or behavior changes, and moves more slowly. Adult MLD, which starts after 16, often first appears as personality changes, psychiatric symptoms or declining work performance, and can progress over decades, with stretches of stability.

Causes & Risk Factors

MLD is caused by changes in a single gene, usually the ARSA gene, which carries instructions for an enzyme called arylsulfatase A. A small number of people instead have changes in a related gene, PSAP, that makes a helper protein the enzyme needs. Either way, sulfatides cannot be cleared and slowly poison the myelin-making cells. The condition is inherited in an autosomal recessive pattern: a person develops MLD only when both copies of the gene are affected, one from each parent. Parents are usually healthy carriers, and when both parents carry it, each pregnancy has a one in four chance of a child with MLD. Nothing a parent did during pregnancy or a person does in daily life causes it. The specific gene changes a person has influence how much enzyme activity remains, which is one reason some people develop symptoms in infancy and others not until adulthood.

How It's Diagnosed

Early signs are often subtle and easy to attribute to something else, such as a toddler who seems late to walk or a teenager whose grades slip. When MLD is suspected, a neurologist examines the person and usually orders an MRI of the brain, which can show the damaged white matter. Nerve conduction tests can show that the nerves to the limbs are affected too. The diagnosis is confirmed with laboratory and genetic tests. A blood test measures arylsulfatase A activity, but low activity alone is not proof: carriers and people with harmless gene variants called pseudodeficiency alleles also have low readings without ever getting sick. That is why clinicians also measure sulfatides in the urine, which are raised in true MLD, and sequence the ARSA gene to identify the specific changes. A few US states and some European countries now screen newborns for MLD, which can find affected babies before symptoms appear, but most people are still diagnosed after symptoms begin.

Treatment Options

There is no treatment that reverses damage already done, so the most important factor in what treatment can achieve is timing. Both disease-modifying options work by giving the body a lasting source of the missing enzyme, and both work best before symptoms start. For children with late infantile MLD who do not yet have symptoms, and for children with early juvenile MLD who have no or only early symptoms, the US Food and Drug Administration approved a one-time gene therapy, atidarsagene autotemcel (Lenmeldy), in 2024. The child's own blood-forming stem cells are collected, given a working copy of the ARSA gene in a laboratory and infused back. In studies comparing treated children with untreated children, most treated children kept developing motor and thinking skills, and children with the late infantile form lived longer. It is not a simple procedure: the child first receives busulfan chemotherapy to make room for the new cells, which brings weeks of low blood counts and a substantial risk of serious infection, and lifelong follow-up includes yearly checks for blood cancer. It is not approved for children whose symptoms are already advanced, or for older-onset forms. For late juvenile and adult MLD, the established option is a stem cell transplant from a matched donor. Long-term studies suggest it can slow the disease and improve daily functioning, most clearly when done before symptoms, but it does not always stop progression, and it carries risks such as graft-versus-host disease, in which donor immune cells attack the body, and treatment-related death. Donor transplant has not shown benefit in late infantile MLD. The evidence for both treatments comes from non-randomized studies, so expected benefit is discussed case by case at specialized centers. For everyone with MLD, supportive care matters a great deal. Medicines can ease muscle stiffness, spasms, seizures and pain. Physical, occupational and speech therapy help preserve movement and communication for as long as possible, and nutrition support, sometimes including a feeding tube, addresses swallowing problems. For adults, treatment of psychiatric symptoms is part of care.

What to Expect

The course depends mostly on the form and on whether treatment happened early. Untreated late infantile MLD progresses quickly, over a few years, from loss of walking and speech to needing full-time care, and children typically do not survive past childhood. Juvenile and adult forms move more slowly; people with adult-onset MLD may live 20 to 30 years after diagnosis, with periods of relative stability and periods of faster decline. Children treated early with gene therapy can have a very different course, though some still lose motor skills, and long-term outcomes beyond the first decade are still being studied. As the disease advances, families often manage mobility equipment, seizures, incontinence, feeding and communication needs, and the caregiving load can be heavy. Care usually involves a team that may include a neurologist, a metabolic or genetics specialist, therapists, a palliative care team and social workers. MLD also commonly affects the gallbladder, causing thickening, polyps or stones, and occasionally bleeding or cancer, even in children and after treatment, so regular gallbladder ultrasounds are often part of follow-up. Genetic counseling helps relatives understand carrier testing and options for future pregnancies.

When to Seek Help

Ask for an evaluation if a young child stops gaining milestones or loses skills such as walking or talking, or if an older child or adult shows unexplained clumsiness, declining school or work performance, or new psychiatric changes alongside movement problems. If a child in the family has been diagnosed, ask right away about testing brothers and sisters, even if they seem healthy, because treatment works best before symptoms and most children diagnosed early are siblings of an affected child. For someone already diagnosed, contact the care team promptly about new seizures, worsening swallowing or choking with meals, or belly pain. Vomiting blood or passing black or bloody stool, which can come from gallbladder bleeding in MLD, needs emergency care.

Questions to Ask Your Doctor

  1. 1.Which form of MLD is this, and how confident are we about the expected course?
  2. 2.Is gene therapy or a donor stem cell transplant still an option at this stage, and what would it realistically achieve?
  3. 3.Should brothers, sisters or other relatives be tested now, and how quickly?
  4. 4.Which specialists and support services should be part of care, and how often will we check the gallbladder and other organs?
  5. 5.What changes should we prepare for over the next year, and how can we plan for them?

Last reviewed • Oct 2026

Educational content, not medical advice.